The Food and Drug Administration recently approved Johnson & Johnson's best-selling drug Stelara to treat adults with Crohn's disease, reported Reuters.
Stelara was first approved in 2009 to treat psoriasis and psoriatic arthritis.
The anti-inflammatory drug, which posted $2.5 billion in sales for 2015, is one of New Brunswick, N.J.-based Johnson & Johnson's biggest revenue generators.
The FDA based its approval on late-stage study results that show Stelara successfully treated patients with moderate-to-severe Crohn's disease who did not respond to traditional medications.
More articles on supply chain:
Red Cross: Blood donations still needed to replenish supply
FDA approves handheld device to assess traumatic brain injury
Mylan underreported EpiPen profits by 60% at Congressional hearing